Viewing data from:

COMPRO

ANDA

PROCHLORPERAZINE | A040246 | PADAGIS US LLC

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 1 NDC

Highest NADAC/Unit

$6.77

per ea

Lowest NADAC/Unit

$6.77

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00574722612COMPRO 25 MG SUPPOSITORY	$6.77	EA	—	$4.92	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Compro (2024)

Total Spending

$1.2M

Total Claims

10,507

Beneficiaries

7,185

Avg Cost/Unit

$6.58

Spending Trend

$1.3M(2019)→$1.3M(2020)→$1.2M(2021)→$1.1M(2022)→$1.3M(2023)→$1.2M(2024)

YoY Change:-14.7%

5yr CAGR:-3.9%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs4 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TRIFARMA SPAPROCHLORPERAZINE BASE

DMF 198902006

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPROCHLORPERAZINE

DMF 314962017

LONZA RIVERSIDEInactivePROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE,PROCHLORPERAZINE MALEATE

DMF 28821977

ORCHIMIE SA (PRODUITS CHIMIQUES ET BIOCHIMIQUES)InactivePROCHLORPERAZINE

DMF 58031985

FINE CHEMICALS CORP PTY LTDInactivePROCHLORPERAZINE DIMALEATE

DMF 75981988

FINE CHEMICALS CORPInactivePROCHLORPERAZINE MESYLATE

DMF 97951992

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 28, 2000	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 25MG

0 patents0 exclusivities▴

SUPPOSITORY;RECTAL | Approved: Jun 28, 2000

No patent or exclusivity listings for this strength.